ArticlemAbs
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04466150 (Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset), which is not on this map. Cited by 214 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Who cites it
214 citing papers in PubMed, 2 syntheses or guidelines pooled it, 372 citations in OpenAlex.
- A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.The oncologist · 2024Pooled it
- The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.CNS drugs · 2022Pooled it
- Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.Journal of neurology · 2025Trial
- Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Trial
- Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Trial
- Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.European journal of neurology · 2022Trial
- Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.European journal of neurology · 2022Trial
- Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.British journal of clinical pharmacology · 2021Trial
- Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.British journal of clinical pharmacology · 2019Trial
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Characterization of Full-Length Antibody Complexes Through HDX-Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD-L1 Interaction.Angewandte Chemie (International ed. in English) · 2026Article
- Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.Journal of neurology · 2026Observational
- Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison.Journal of neurology · 2026Article
- Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.Clinical pharmacology and therapeutics · 2026Review
- Comparative In Vitro Apoptotic Activity of Two Chimeric Anti-CD99 Antibodies Recognizing Distinct CD99 Regions in T-ALL Models.Biomedicines · 2026Article
- Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma.Life (Basel, Switzerland) · 2026Article
- Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis.Neurology and therapy · 2026Article
- Subcutaneous ofatumumab for remission maintenance in pediatric idiopathic nephrotic syndrome: a case series.Clinical kidney journal · 2026Article
- Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".Annals of neurology · 2026Article
- Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy.Nuclear medicine and molecular imaging · 2026Review
154 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several novel anti-CD20 monoclonal antibodies are currently in development with the aim of improving the treatment of B cell malignancies. Mutagenesis and epitope mapping studies have revealed differences between the CD20 epitopes recognized by these antibodies. Recently, X-ray crystallography studies confirmed that the Type I CD20 antibody rituximab and the Type II CD20 antibody obinutuzumab (GA101) differ fundamentally in their interaction with CD20 despite recognizing a partially overlapping epitope on CD20. The Type I CD20 antibodies rituximab and ofatumumab are known to bind to different epitopes. The differences suggest that the biological properties of these antibodies are not solely determined by their core epitope sequences, but also depend on other factors, such as the elbow hinge angle, the orientation of the bound antibody and differential effects mediated by the Fc region of the antibody. Taken together, these factors may explain differences in the preclinical properties and clinical efficacy of anti-CD20 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.